What is NewLimit?
Founded in 2022, NewLimit is at the forefront of a new wave of biotech innovation, aiming to create therapies that not only extend lifespan but crucially enhance health spans. This focus on 'healthspan' – the period of life spent in good health – is gaining traction, as exemplified by other recent ventures in the sector. NewLimit's scientific mission involves reprogramming aged cells, a complex biological process with the potential to revolutionize how age-related diseases are treated and managed, offering patients a future with improved quality of life.
How much funding has NewLimit raised?
NewLimit has raised a total of $170M across 2 funding rounds:
Series A
$40M
Series B
$130M
Series A (2023): $40M with participation from Dimension Capital Management, Founders Fund, and Kleiner Perkins
Series B (2025): $130M led by Khosla Ventures, The Human Capital Institute, and Kleiner Perkins
Key Investors in NewLimit
Khosla Ventures
Khosla Ventures is a venture capital firm known for investing in a wide range of technology companies, often focusing on disruptive innovations and early-stage ventures.
The Human Capital Institute
The Human Capital Institute (HCI) specializes in providing strategic HR training, certifications, and conferences aimed at enhancing the skills of HR professionals. Their offerings include a variety of certification programs, workshops, and corporate training solutions designed to foster leadership development and improve employee engagement.
Kleiner Perkins
Kleiner Perkins is a Menlo Parkbased venture capital firm that raises dedicated funds and invests in early and growthstage technology and lifescience companies, backing founders across consumer, enterprise, healthcare, and climate/hard tech with capital and operational support from seed through IPO or acquisition.
What's next for NewLimit?
With the infusion of $130M in a major strategic investment, NewLimit is poised for accelerated growth and development. This capital injection is expected to fuel further research and development, potentially enabling the company to advance its therapeutic candidates through clinical trials and scale its operations. The company's focus on reprogramming cellular aging positions it within a high-growth market driven by increasing demand for longevity solutions. Future strategic partnerships and further funding rounds may be anticipated as NewLimit progresses towards its goal of making impactful medicines that significantly extend patient health spans.
See full NewLimit company page
